Compare · FRMM vs NVS
FRMM vs NVS
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- FRMM operates in Finance, while NVS operates in Health Care - the two are in different parts of the market.
- NVS is the larger of the two at $305.69B, about 9542.8x FRMM ($32.0M).
- Over the past year, FRMM is down 81.6% and NVS is up 21.8% - NVS leads by 103.4 points.
- FRMM has been more active in the news (6 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Novartis AG
- Price
- -
- -
- Market cap
- $32.0M
- $305.69B
- 1M return
- -36.70%
- +6.36%
- 1Y return
- -81.57%
- +21.79%
- Industry
- Finance: Consumer Services
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 6
- 5
- Recent ratings
- 1
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest FRMM
- Amendment: SEC Form SCHEDULE 13G/A filed by Forum Markets Incorporated
- SEC Form 10-Q filed by Forum Markets Incorporated
- Forum Markets Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Forum Markets Reports Third Quarter 2026 Financial Results
- Forum Edge AI Announces $94.4 Million Definitive AI Cloud Services Compute Agreement with Fireworks
- SEC Form 8-K filed by Forum Markets Incorporated
- Forum Announces Third Quarter 2026 Earnings Release Date and Webcast Details
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Forum Markets Announces Joint Venture with Edge Node AI to Deploy Inference AI Compute Across the U.S. at Existing Powered Data Sites and Mobile Communications Towers
- Forum Markets Incorporated filed SEC Form 8-K: Leadership Update
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank